Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States. Although advances in surgery, radiotherapy, and hormone therapy have ...

Achieving a PSA nadir of less than 0.2 ng/mL is needed for optimal mCSPC outcomes. For real-world patients with metastatic castration-sensitive prostate cancer (mCSPC), reaching a PSA nadir less than ...

ADT intensification may not improve prostate cancer survival. Explore real-world findings and key risk factors. Read more.

Real-world outcomes in metastatic prostate cancer patients with ctDNA-detected SPOP mutations. a Sensitivity analysis of all ADT modalities. b Adjusted analysis of current ADT modalities. c Adjusted ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

Adding metformin to androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Quality of life (QoL) results from STAMPEDE. Safety profile of darolutamide + ADT ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...

Vasomotor symptoms (VMS) including hot flashes are a common complaint among men undergoing androgen deprivation therapy (ADT) for prostate cancer. Although the symptoms are more widely associated with ...

177Lu-PSMA-617 combined with ADT and ARPI reduced progression or death risk by 28% in PSMA-positive mHSPC patients. The PSMAddition trial showed significant rPFS improvement and a positive OS trend, ...